Canada · Delayed Price · Currency is CAD PharmaCorp Rx Statistics
Total Valuation
PharmaCorp Rx has a market cap or net worth of CAD 88.78 million. The enterprise value is 70.31 million.
| Market Cap | 88.78M |
| Enterprise Value | 70.31M |
Important Dates
The next estimated earnings date is Monday, August 17, 2026.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCorp Rx has 174.08 million shares outstanding. The number of shares has increased by 18.79% in one year.
| Current Share Class | 174.08M |
| Shares Outstanding | 174.08M |
| Shares Change (YoY) | +18.79% |
| Shares Change (QoQ) | +23.37% |
| Owned by Insiders (%) | 10.62% |
| Owned by Institutions (%) | 6.23% |
| Float | 155.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 25.50 |
| PS Ratio | 3.69 |
| PB Ratio | 1.68 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.42, with a Debt / Equity ratio of 0.08.
| Current Ratio | 9.42 |
| Quick Ratio | 8.35 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.77 |
| Interest Coverage | -17.55 |
Financial Efficiency
Return on equity (ROE) is -3.70% and return on invested capital (ROIC) is -4.68%.
| Return on Equity (ROE) | -3.70% |
| Return on Assets (ROA) | -1.92% |
| Return on Invested Capital (ROIC) | -4.68% |
| Return on Capital Employed (ROCE) | -2.52% |
| Weighted Average Cost of Capital (WACC) | -18.45% |
| Revenue Per Employee | 4.82M |
| Profits Per Employee | -323,014 |
| Employee Count | 5 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 6.25 |
Taxes
In the past 12 months, PharmaCorp Rx has paid 470,050 in taxes.
| Income Tax | 470,050 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.25% in the last 52 weeks. The beta is -4.31, so PharmaCorp Rx's price volatility has been lower than the market average.
| Beta (5Y) | -4.31 |
| 52-Week Price Change | +6.25% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 54.47 |
| Average Volume (20 Days) | 119,659 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCorp Rx had revenue of CAD 24.08 million and -1.62 million in losses. Loss per share was -0.01.
| Revenue | 24.08M |
| Gross Profit | 9.47M |
| Operating Income | -1.52M |
| Pretax Income | -1.08M |
| Net Income | -1.62M |
| EBITDA | -573,638 |
| EBIT | -1.52M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 23.38 million in cash and 4.48 million in debt, with a net cash position of 18.90 million or 0.11 per share.
| Cash & Cash Equivalents | 23.38M |
| Total Debt | 4.48M |
| Net Cash | 18.90M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | 52.83M |
| Book Value Per Share | 0.30 |
| Working Capital | 24.77M |
Cash Flow
In the last 12 months, operating cash flow was -792,827 and capital expenditures -146,106, giving a free cash flow of -938,933.
| Operating Cash Flow | -792,827 |
| Capital Expenditures | -146,106 |
| Depreciation & Amortization | 943,505 |
| Net Borrowing | 2.78M |
| Free Cash Flow | -938,933 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 39.32%, with operating and profit margins of -6.30% and -6.71%.
| Gross Margin | 39.32% |
| Operating Margin | -6.30% |
| Pretax Margin | -4.48% |
| Profit Margin | -6.71% |
| EBITDA Margin | -2.38% |
| EBIT Margin | -6.30% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCorp Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.79% |
| Shareholder Yield | -18.79% |
| Earnings Yield | -1.82% |
| FCF Yield | -1.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for PharmaCorp Rx is 0.67, which is 31.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 0.67 |
| Price Target Difference | 31.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 60.37% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaCorp Rx has an Altman Z-Score of 4.39 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.39 |
| Piotroski F-Score | 3 |